The pharmaceutical lobby strongly opposed the Biden administration’s plan to directly negotiate drug prices for 10 medications with Medicare. PhRMA argued this will hurt innovation, but advocates note that drug companies make 76% more than needed for R&D. Eliquis, which costs Medicare over $16 billion, will be subject to negotiations. The policy was enabled by the Inflation Reduction Act, which PhRMA spent millions lobbying against. PhRMA sued over the negotiations, but the DOJ moved to dismiss the case. Advocates believe this defeat of Big Pharma will not be the last as negotiations may expand to over 100 drugs in the future, greatly helping seniors and people with disabilities access affordable medications.

  • @nob0dy@beehaw.org
    link
    fedilink
    2510 months ago

    A win is a win, so the Americans should take it were they can but this will just push costs elsewhere. I image they’ll just recoup the profit on the next 10 most popular drugs were they can gouge. We really need to start talking about comprehensive healthcare reform, a revolution so to speak, that stops this stupid patchwork and actually give us universal healthcare.

    • @greenskye@beehaw.org
      link
      fedilink
      910 months ago

      It opens a crack to do it again. And again and again. If it didn’t hurt them they wouldn’t fight it so hard. But I do agree we should be trying for something more comprehensive. That said, I don’t think the country is currently capable of doing something like that. We’re too broken.

    • @DrPop
      link
      510 months ago

      I I’m off the firm belief life saving medicine shouldn’t cost the consumer anything. The government should be in charge and negotiate pricing with the businesses. But they’re rather bleed us dry.

    • @morrowind@lemmy.ml
      link
      fedilink
      210 months ago

      I image they’ll just recoup the profit on the next 10 most popular drugs were they can gouge.

      If they could gouge them, they probably would be doing so already.